Pharmacokinetically guided dose escalation phase I clinical trials. commentary and proposed guidelines.

Pharmacokinetics Eortc

Type: Article

Publication Date: 1987-01-01

Citations: 59

View

Locations

European Journal of Cancer and Clinical Oncology - View

Similar Works

Action	Title	Year	Authors
+	Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines	1987
+	Dose selection in phase I trials: a review of development programs from approved drugs to investigate intrinsic and extrinsic factors on pharmacokinetics and safety.	2024	Rüdiger Kaspera Y Shitara
+	Use of Pharmacokinetics and Pharmacodynamics in Preclinical Studies to Guide Dosage Escalation Schemes in Phase I Studies of Anticancer Drugs	1993	Jerry M. Collins
+	11. Phase I studies and clinical pharmacokinetic studies	1998	Hughes Griffin Calvert J R Johnston Kerr Lee Newell Boddy
+	Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials	2020	Lingzhi Wang Wan Qin Chong Pei Shi Ong Boon Cher Goh
+	Pharmacokinetics in Phase I Clinical Trial	1987	Tatsuji Iga
+ PDF Chat	Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials	2017	M. Iftakhar Alam Barbara Bogacka D. Stephen Coad
+	Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology	2003	Ch. van Kesteren Ron A. A. Mathôt Jos H. Beijnen Jan H.M. Schellens
+ PDF Chat	Early phase clinical trials to identify optimal dosing and safety	2014	Natalie Cook Aaron R. Hansen Lillian L. Siu Albiruni R. Abdul Razak
+	Preclinical Pharmacology and Phase I Clinical Trials	1994	H.A. Burris
+	Dose Optimization of Oncology Drugs: A Clinical and Regulatory Perspective	2024	Marjorie E. Zettler
+	Doubling of dosage in phase I studies . Safe	1964	Jacques Louis
+	Studies for Phase I Clinical Trials	2007	Chen Li-ping
+	The dose-response relationship in Phase I clinical trials and beyond use, meaning, and assessment	2000	Gérard Emilien
+	Pharmacokinetic/Pharmacodynamic for Dose Selection: Decreasing the Risk of Toxicity and Suboptimal Efficacy	2008	Sujata M. Bhavnani
+	Design and Analysis of Dose Escalation Studies to Mitigate Dose-Limiting Adverse Effects	2006	Larry Z. Shen Mark Fineman Alain Baron
+	Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue	2016	Nuria Kotecki Ahmad Awada Jacques Bonneterre Mohamed Hebbar Antoine Adenis Alexis B. Cortot Sophie Cousin Stéphanie Clisant Alain Duhamel Nicolas Penel
+	Efficacy for Targeted Agents Seamless Phase I-II Trial Design for Assessing Toxicity and	2011	Antje Hoering Mike LeBlanc John Crowley
+	Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead	2023	Pooneh Soltantabar Hoi‐Kei Lon Kourosh Parivar Diane D. Wang Mohamed Elmeliegy
+	Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents	2012	Antje Hoering Michael LeBlanc John Crowley

Cited by (16)

Action	Title	Year	Authors
+ PDF Chat	EORTC new drug development office coordinating and monitoring programme for phase I and II trials with new anticancer agents	1991	Gilberto Schwartsmann J. Wanders I. Koier H. R. Franklin O. Dalesio H.W. Hornstra M. van Glabbeke J. Renard A.T. van Oosterom Stan B. Kaye
+	Use of Pharmacokinetics and Pharmacodynamics in Preclinical Studies to Guide Dosage Escalation Schemes in Phase I Studies of Anticancer Drugs	1993	Jerry M. Collins
+	Phase II Clinical Trials in Oncology	1997	Khater Christine Paul B. Laub James M. Gallo André Rogatko Peter J. O’Dwyer
+ PDF Chat	The Continual Reassessment Method (CRM) and Related Topics^\|^mdash;A Review. Part I: Understanding the CRM for Dose-Finding Studies.	2012	Takashi Daimon
+	Phase I Trial Design and Methodology	1997	Deborah Toppmeyer
+ PDF Chat	抗癌剤のトキシコキネティックス・トキシコダイナミックス : ヒトにおける抗癌剤の最大耐用量(MTD)の予測とpharmacokinetically guided dose escalation法	1993	布施英一稲葉實 Yuichi Sugiyama
+	Concentration-Controlled Trials	1995	A. E. Johnston David W. Holt
+	Handbook of Statistics in Clinical Oncology	2005
+	Choice of starting dose and escalation for phase I studies of antitumor agents	1992	John S. Penta Gary L. Rosner Donald L. Trump
+	Pharmacokinetic Optimisation of Anticancer Therapy	1991	Jan Liliemark Curt Peterson
+	Pharmacologically Based Phase I Trials in Cancer Chemotherapy	1994	David R. Newell
+	Rule-Based Designs Considering Toxicity Alone	2019	Takashi Daimon Akihiro Hirakawa Shigeyuki Matsui
+	Perceptions of cancer patients and their physicians involved in phase I trials.	1995	Claire Daugherty Mark J. Ratain Eugene C. Grochowski Carol Stocking Eric Kodish Rosemarie Mick Mark Siegler
+ PDF Chat	The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials	2008	A H Calvert Ruth Plummer
+	Predictive value of preclinical toxicology studies for platinum anticancer drugs.	1999	Diana L. Clark Paul A. Andrews David Smith J J DeGeorge Robert Justice Julie Beitz
+	Toxicology and Regulatory Aspects of Platinum Drugs	2000	Diana L. Clark Paul A. Andrews David Smith Joseph J. DeGeorge Robert Justice Julie Beitz

Citing (0)

Action	Title	Year	Authors